PRESS RELEASE published on 07/29/2025 at 07:00, 1 year 1 month ago Relief Therapeutics Announces Proposed Business Combination with NeuroX, successor to MindMaze Relief Therapeutics to merge with NeuroX, successor to MindMaze, creating a SIX-listed, AI-driven health tech company. Transaction expected to close in Q4 2025 Business Combination Relief Therapeutics MindMaze NeuroX AI-driven Health Tech
BRIEF published on 06/20/2025 at 07:05, 1 year 2 months ago Relief Therapeutics Faces FDA Setback for RLF-TD011 QIDP Designation RLF-TD011 Orphan Drug FDA Response Epidermolysis Bullosa QIDP Designation
BRIEF published on 06/20/2025 at 07:05, 1 year 2 months ago Relief Therapeutics fait face à un revers de la FDA concernant la désignation QIDP du RLF-TD011 RLF-TD011 Médicament Orphelin Réponse De La FDA Epidermolyse Bulleuse Désignation QIDP
PRESS RELEASE published on 06/20/2025 at 07:00, 1 year 2 months ago Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011 Relief Therapeutics receives FDA response on QIDP request for RLF-TD011, impacting EB treatment strategy with Orphan Drug and Rare Pediatric Disease designations Relief Therapeutics RLF-TD011 FDA Response Epidermolysis Bullosa QIDP Request
BRIEF published on 06/12/2025 at 11:05, 1 year 2 months ago Relief Therapeutics Announces Results of Annual General Meeting Financial Statements Shareholder Approval Annual Meeting Board Elections Compensation Approval
BRIEF published on 06/12/2025 at 11:05, 1 year 2 months ago Relief Therapeutics annonce les résultats de son assemblée générale annuelle États Financiers Réunion Annuelle Approbation Des Actionnaires Élections Du Conseil D'administration Approbation De L'indemnisation
PRESS RELEASE published on 06/12/2025 at 11:00, 1 year 2 months ago Relief Therapeutics Announces Results of Annual General Meeting Relief Therapeutics announces results of its Annual General Meeting with shareholders approving all proposals by a large majority. AGM covers key agenda items and re-election of board members and auditors Board Of Directors Annual General Meeting Shareholders Relief Therapeutics AGM Results
BRIEF published on 05/22/2025 at 07:05, 1 year 3 months ago Relief Therapeutics Secures FDA Rare Pediatric Disease Designation for RLF-TD011 FDA Relief Therapeutics RLF-TD011 Epidermolysis Bullosa Rare Pediatric Disease
BRIEF published on 05/22/2025 at 07:05, 1 year 3 months ago Relief Therapeutics obtient la désignation de maladie pédiatrique rare de la FDA pour le RLF-TD011 FDA THÉRAPEUTIQUE DE SECOURS RLF-TD011 Epidermolyse Bulleuse Maladie Pédiatrique Rare
PRESS RELEASE published on 05/22/2025 at 07:00, 1 year 3 months ago Relief Therapeutics Receives FDA Rare Pediatric Disease Designation for RLF-TD011 Relief Therapeutics granted FDA Rare Pediatric Disease Designation for RLF-TD011 in treating epidermolysis bullosa, a rare genetic skin disorder. Potent antimicrobial & anti-inflammatory activity shown FDA Relief Therapeutics RLF-TD011 Epidermolysis Bullosa Rare Pediatric Disease Designation
Published on 09/11/2026 at 04:00, 9 hours 1 minute ago Torq Announces Debt Settlement and Corporate Update
Published on 09/10/2026 at 22:25, 14 hours 36 minutes ago Pathfinder Ventures Announces Appointment of Mickey Perret as Chief Executive Officer
Published on 09/10/2026 at 15:20, 21 hours 41 minutes ago MicroVision to Preview Next-Generation Lidar-Based Perception Platform at IAA Transportation 2026
Published on 09/10/2026 at 15:00, 22 hours 1 minute ago All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failure (IF)
Published on 09/11/2026 at 11:43, 1 hour 17 minutes ago Skyborn reaches Financial Close on the Gennaker offshore wind farm project
Published on 09/11/2026 at 11:35, 1 hour 25 minutes ago EQS-Adhoc: Correction of a release from 10/09/2026, 19:35 CET/CEST - United Internet AG: Group subsidiaries 1&1 AG and IONOS Group SE launch transformation programs
Published on 09/11/2026 at 11:30, 1 hour 31 minutes ago Galimedix Therapeutics to present functional feasibility data from Phase 2 eDREAM study in geographic atrophy at 26th EURETINA Congress
Published on 09/11/2026 at 10:15, 2 hours 45 minutes ago TCMA Receives Two National Awards, Highlighting Thailand’s Cement Industry Progress Towards Net Zero 2050
Published on 09/11/2026 at 07:00, 6 hours 1 minute ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 6 hours 1 minute ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 17 hours 31 minutes ago Availability of the 2026 Interim Financial Report
